BioTelemetry Inc. (NASDAQ:BEAT)’s share price traded up 3.2% during mid-day trading on Wednesday . The stock traded as high as $16.69 and last traded at $16.60, with a volume of 140,916 shares traded. The stock had previously closed at $16.08.

Separately, Zacks Investment Research cut BioTelemetry from a “hold” rating to a “sell” rating in a research report on Tuesday, April 19th.

The stock has a market cap of $461.09 million and a price-to-earnings ratio of 41.85. The firm has a 50 day moving average price of $16.22 and a 200-day moving average price of $12.96.

BioTelemetry (NASDAQ:BEAT) last issued its quarterly earnings results on Tuesday, April 26th. The company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.10 by $0.10. During the same period in the previous year, the business posted $0.06 EPS. The company had revenue of $48.60 million for the quarter, compared to the consensus estimate of $46.54 million. The business’s revenue for the quarter was up 12.0% on a year-over-year basis. On average, equities analysts expect that BioTelemetry Inc. will post $0.71 earnings per share for the current year.

Several institutional investors recently modified their holdings of the company. Gabelli Funds LLC bought a new position in shares of BioTelemetry during the fourth quarter valued at approximately $1,190,000. Teton Advisors Inc. boosted its position in shares of BioTelemetry by 26.3% in the fourth quarter. Teton Advisors Inc. now owns 135,100 shares of the company’s stock valued at $1,578,000 after buying an additional 28,100 shares during the last quarter. Russell Frank Co boosted its position in shares of BioTelemetry by 58.9% in the fourth quarter. Russell Frank Co now owns 249,457 shares of the company’s stock valued at $2,933,000 after buying an additional 92,455 shares during the last quarter. 1492 Capital Management LLC boosted its position in shares of BioTelemetry by 11.4% in the fourth quarter. 1492 Capital Management LLC now owns 321,761 shares of the company’s stock valued at $3,758,000 after buying an additional 32,932 shares during the last quarter. Finally, Royce & Associates LLC boosted its position in shares of BioTelemetry by 102.2% in the fourth quarter. Royce & Associates LLC now owns 606,700 shares of the company’s stock valued at $7,086,000 after buying an additional 306,700 shares during the last quarter.

BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.